Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]

Huilin Tang, Jiali Han, Yiqing Song

Research output: Contribution to journalLetter

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)2538-2539
Number of pages2
JournalDiabetologia
Volume60
Issue number12
DOIs
StatePublished - Dec 1 2017

Keywords

  • Bladder cancer
  • Empagliflozin
  • SGLT2 inhibitors

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]. / Tang, Huilin; Han, Jiali; Song, Yiqing.

In: Diabetologia, Vol. 60, No. 12, 01.12.2017, p. 2538-2539.

Research output: Contribution to journalLetter

@article{00c94897a77645858dce5b27f1ff2701,
title = "Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]",
keywords = "Bladder cancer, Empagliflozin, SGLT2 inhibitors",
author = "Huilin Tang and Jiali Han and Yiqing Song",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s00125-017-4431-z",
language = "English (US)",
volume = "60",
pages = "2538--2539",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]

AU - Tang, Huilin

AU - Han, Jiali

AU - Song, Yiqing

PY - 2017/12/1

Y1 - 2017/12/1

KW - Bladder cancer

KW - Empagliflozin

KW - SGLT2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85029578933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029578933&partnerID=8YFLogxK

U2 - 10.1007/s00125-017-4431-z

DO - 10.1007/s00125-017-4431-z

M3 - Letter

C2 - 28920156

AN - SCOPUS:85029578933

VL - 60

SP - 2538

EP - 2539

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 12

ER -